Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer-Reference-Cited by-同舟云学术

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Published:2019-12-05 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Hu Chen-Yu,Xu Xiang-Ming,Hong Bo,Wu Zhi-Gang,Qian Yun,Weng Tian-Hao,Liu Yi-Zhi,Tang Tao-Ming,Wang Ming-Hai,Yao Hang-Ping

Funder

National Natural Science Foundation of China

Natural Science Foundation of Zhejiang Province

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference50 articles.

1. Advanced pancreatic carcinoma: current treatment and future challenges;Stathis;Nat Rev Clin Oncol.,2010

2. Pancreatic cancer;Vincent;Lancet.,2011

3. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res.,2014

4. A novel putative receptor protein tyrosine kinase of the met family;Ronsin;Oncogene.,1993

5. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors;Park;Proc Natl Acad Sci USA.,1987

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies;Cancers;2022-04-18

2. Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs – a review;RSC Advances;2022

3. RON in hepatobiliary and pancreatic cancers: Pathogenesis and potential therapeutic targets;World Journal of Gastroenterology;2021-05-28

4. The MSP‐RON pathway regulates liver fibrosis through transforming growth factor beta‐dependent epithelial–mesenchymal transition;Liver International;2021-04-19

5. Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase;Drug Discovery Today;2021-01